Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility

Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
Home Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label Supplement Group Targets Consumer Education ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace Human Genome Project Leads to Innovative Healthcare NPIcenter’s Career Center targets nutraceutical Industry Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders Editorial: An Exercise in Synergy NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway FDA Presents Compliance Guide for Structure/Function Claims New TrimFit® Bars Redefine Energy Bar Category New TrimFit® Bars Redefine Energy Bar Category Probiata® Offers Safe, Natural and Effective Alternative Alive & Well with Michelle Harris Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com Consumers Search for Healthy Cleaning Products That Work Nordic Naturals: Omega 3 Fatty Acids KAVA ADVISORY: Health Canada is advising consumers not to use any products containing kava Modern Science Confirms Ancient Wisdom! Modern Science Confirms Ancient Wisdom! "Natural" or "Plant-Derived" Labeling Can Mislead CDN: Natural Health Products Report - Update NPI Editorial: Are we using Best Practices? AHPA Update: Kava Information from the AHPA Executive Committee European Commission Proposes Registration Scheme for Herbal Medicine to Avoid Need for Testing Statement on Kava in New Zealand BICL Discontinues Kava Sales; Health Canada Issues Consumer Warning BICL Discontinues Kava Sales; Health Canada Issues Consumer Warning SunOpta Announces First Quarter 2008 Results SunOpta Inc. (STKL) (CA:SOY) has announced FY08 Q1 results, reporting revenues of $230,444,000 as compared to $183,500,000 in the first quarter of 2007, with earnings of $1,486,000 or $0.02 per diluted common share as compared to 2007 first quarter earnings of $1,055,000 or $0.02 per diluted common share. Greg Horn Named Solbar North American Business Director Solbar Industries Ltd. has announced the appointment of Greg Horn to direct the company's business, marketing and sales activities in North America (U.S. and Canada), beginning August 1st, 2008, to be responsible for implementing Solbar's business marketing plan focused on specialty soy proteins including isolates, functional and textured soy concentrates and Solbar's Bontex steam-textured soy proteins. Greg Horn Named Solbar North American Business Director Solbar Industries Ltd. has announced the appointment of Greg Horn to direct the company's business, marketing and sales activities in North America (U.S. and Canada), beginning August 1st, 2008, to be responsible for implementing Solbar's business marketing plan focused on specialty soy proteins including isolates, functional and textured soy concentrates and Solbar's Bontex steam-textured soy proteins. Greg Horn Named Solbar North American Business Director Solbar Industries Ltd. has announced the appointment of Greg Horn to direct the company's business, marketing and sales activities in North America (U.S. and Canada), beginning August 1st, 2008, to be responsible for implementing Solbar's business marketing plan focused on specialty soy proteins including isolates, functional and textured soy concentrates and Solbar's Bontex steam-textured soy proteins. Greg Horn Named Solbar North American Business Director Solbar Industries Ltd. has announced the appointment of Greg Horn to direct the company's business, marketing and sales activities in North America (U.S. and Canada), beginning August 1st, 2008, to be responsible for implementing Solbar's business marketing plan focused on specialty soy proteins including isolates, functional and textured soy concentrates and Solbar's Bontex steam-textured soy proteins. Reliv International Reports Second-Quarter Results; Restructures European Operations Reliv International, Inc. (RELV) has announced FY08 Q12 results, reporting net sales of $24.0 million, compared to net sales of $26.3 million in the second quarter last year, with net income of $569,000 or $0.04 per diluted share, compared to net income of $823,000 or $0.05 per diluted share in the second quarter of 2007. Reliv International Reports Second-Quarter Results; Restructures European Operations Reliv International, Inc. (RELV) has announced FY08 Q12 results, reporting net sales of $24.0 million, compared to net sales of $26.3 million in the second quarter last year, with net income of $569,000 or $0.04 per diluted share, compared to net income of $823,000 or $0.05 per diluted share in the second quarter of 2007. Nu Skin Enterprises Reports Second-Quarter 2008 Results Nu Skin Enterprises, Inc. (NUS) has announced FY08 Q2 results, reporting revenue of $321.7 million, a 12 percent improvement over the prior-year period, with earnings per share of $0.32 compared to $0.21 for the same quarter of 2007. Nu Skin Enterprises Reports Second-Quarter 2008 Results Nu Skin Enterprises, Inc. (NUS) has announced FY08 Q2 results, reporting revenue of $321.7 million, a 12 percent improvement over the prior-year period, with earnings per share of $0.32 compared to $0.21 for the same quarter of 2007. Nutraceutical Reports Q3 Results Nutraceutical International Corporation (NUTR) has announced FY08 Q3 results, reporting net sales of $40.5 million compared to $38.7 million for the same quarter prior year, with net income of $2.9 million, or $0.26 diluted earnings per share, compared to net income of $2.9 million, or $0.25 diluted earnings per share, for the same quarter of fiscal 2007. Nutraceutical Reports Q3 Results Nutraceutical International Corporation (NUTR) has announced FY08 Q3 results, reporting net sales of $40.5 million compared to $38.7 million for the same quarter prior year, with net income of $2.9 million, or $0.26 diluted earnings per share, compared to net income of $2.9 million, or $0.25 diluted earnings per share, for the same quarter of fiscal 2007. Balchem Corporation Announces 2nd Quarter 2008 Results Balchem Corporation (BCPC) has announced FY08 Q2 results, reporting net sales of $62.9 million compared to $44.4 million prior year, with net earnings of $4.7 million, an increase of $0.7 million, or 16.2% as compared with the same period last year. Sales of the Food, Pharma and Nutrition segment were $9.5 million, an increase of 19.6% from the prior year comparable quarter. Balchem Corporation Announces 2nd Quarter 2008 Results Balchem Corporation (BCPC) has announced FY08 Q2 results, reporting net sales of $62.9 million compared to $44.4 million prior year, with net earnings of $4.7 million, an increase of $0.7 million, or 16.2% as compared with the same period last year. Sales of the Food, Pharma and Nutrition segment were $9.5 million, an increase of 19.6% from the prior year comparable quarter. PacificHealth Laboratories Reports Second Quarter 2008 Results PacificHealth Laboratories, Inc. (PHLI) has announced Fy08 Q2 results, reporting revenues of $2,370,429 compared to $2,069,889 for the same period in 2007, with a net loss of ($146,608), or ($0.01) per share compared to a net loss of ($127,276), or ($0.01) per share, for the same period in 2007. PacificHealth Laboratories Reports Second Quarter 2008 Results PacificHealth Laboratories, Inc. (PHLI) has announced Fy08 Q2 results, reporting revenues of $2,370,429 compared to $2,069,889 for the same period in 2007, with a net loss of ($146,608), or ($0.01) per share compared to a net loss of ($127,276), or ($0.01) per share, for the same period in 2007. Fenchem Maintains Competitive Vitamin E price The price of Fenchem’s TOCOVET® natural source vitamin E in North America is being maintained within the marketplace, due to large stocks and expanding production. Fenchem Maintains Competitive Vitamin E price The price of Fenchem’s TOCOVET® natural source vitamin E in North America is being maintained within the marketplace, due to large stocks and expanding production. Aquapharm and Croda International Sign Three Year Research Collaboration Agreement Marine biotechnology company Aquapharm Biodiscovery Ltd and Croda International Plc today announced the signing of a collaboration and license agreement in which Croda will have an exclusive license to novel marine derived natural products identified through the collaboration from strains from Aquapharm’s proprietary microbial library for use in topical cosmetic applications in skin and hair care. Aquapharm and Croda International Sign Three Year Research Collaboration Agreement Marine biotechnology company Aquapharm Biodiscovery Ltd and Croda International Plc today announced the signing of a collaboration and license agreement in which Croda will have an exclusive license to novel marine derived natural products identified through the collaboration from strains from Aquapharm’s proprietary microbial library for use in topical cosmetic applications in skin and hair care. Aquapharm and Croda International Sign Three Year Research Collaboration Agreement Marine biotechnology company Aquapharm Biodiscovery Ltd and Croda International Plc today announced the signing of a collaboration and license agreement in which Croda will have an exclusive license to novel marine derived natural products identified through the collaboration from strains from Aquapharm’s proprietary microbial library for use in topical cosmetic applications in skin and hair care. Aquapharm and Croda International Sign Three Year Research Collaboration Agreement Marine biotechnology company Aquapharm Biodiscovery Ltd and Croda International Plc today announced the signing of a collaboration and license agreement in which Croda will have an exclusive license to novel marine derived natural products identified through the collaboration from strains from Aquapharm’s proprietary microbial library for use in topical cosmetic applications in skin and hair care. DNP Notches 8% Second Quarter Increase DNP International has reported an eight percent second quarter increase compared to last year during the same time. DNP Notches 8% Second Quarter Increase DNP International has reported an eight percent second quarter increase compared to last year during the same time. Natural Alternatives International, Inc. Announces Sale of 'As We Change(R)' Assets and Provides Fourth Quarter Revenue Update Natural Alternatives International, Inc. (NAII) has announced that it has sold the "As We Change(R)" catalog and internet business of Real Health Laboratories, Inc., its wholly owned subsidiary, for $2.0 million subject to certain adjustments. Natural Alternatives International, Inc. Announces Sale of 'As We Change(R)' Assets and Provides Fourth Quarter Revenue Update Natural Alternatives International, Inc. (NAII) has announced that it has sold the "As We Change(R)" catalog and internet business of Real Health Laboratories, Inc., its wholly owned subsidiary, for $2.0 million subject to certain adjustments. Whole Foods Market reports third quarter results Whole Foods Market, Inc. has announced FY Q3 results reporting sales of approximately $1.8 billion with comparable store sales increased 2.6% Net income was approximately $33.9 million, and diluted earnings per share were $0.24 Whole Foods Market reports third quarter results Whole Foods Market, Inc. has announced FY Q3 results reporting sales of approximately $1.8 billion with comparable store sales increased 2.6% Net income was approximately $33.9 million, and diluted earnings per share were $0.24 Herbalife announces record Q2 results Herbalife Ltd. (HLF) has announced FY08 Q2 results, reporting net sales of $639.7 million, an increase of 20.7 percent compared to the same period of 2007, with net income of $67.1 million, or $1.01 per diluted share, compared to $48.1 million, or $0.65 per diluted share in the second quarter of 2007. Herbalife announces record Q2 results Herbalife Ltd. (HLF) has announced FY08 Q2 results, reporting net sales of $639.7 million, an increase of 20.7 percent compared to the same period of 2007, with net income of $67.1 million, or $1.01 per diluted share, compared to $48.1 million, or $0.65 per diluted share in the second quarter of 2007. Jamba, Inc. Announces Changes to Its Senior Management Team Jamba, Inc. (JMBA) has announced that Steven R. Berrard, the Company's Chairman of the Board, has assumed the role of interim Chief Executive Officer and President of the Company, replacing Paul E. Clayton, and Karen Luey, Vice President, Controller, and Principal Accounting Officer of the Company, has assumed the role of interim Chief Financial Officer of the Company, replacing Donald D. Breen. Jamba, Inc. Announces Changes to Its Senior Management Team Jamba, Inc. (JMBA) has announced that Steven R. Berrard, the Company's Chairman of the Board, has assumed the role of interim Chief Executive Officer and President of the Company, replacing Paul E. Clayton, and Karen Luey, Vice President, Controller, and Principal Accounting Officer of the Company, has assumed the role of interim Chief Financial Officer of the Company, replacing Donald D. Breen. Jamba, Inc. Announces Changes to Its Senior Management Team Jamba, Inc. (JMBA) has announced that Steven R. Berrard, the Company's Chairman of the Board, has assumed the role of interim Chief Executive Officer and President of the Company, replacing Paul E. Clayton, and Karen Luey, Vice President, Controller, and Principal Accounting Officer of the Company, has assumed the role of interim Chief Financial Officer of the Company, replacing Donald D. Breen. Jamba, Inc. Announces Changes to Its Senior Management Team Jamba, Inc. (JMBA) has announced that Steven R. Berrard, the Company's Chairman of the Board, has assumed the role of interim Chief Executive Officer and President of the Company, replacing Paul E. Clayton, and Karen Luey, Vice President, Controller, and Principal Accounting Officer of the Company, has assumed the role of interim Chief Financial Officer of the Company, replacing Donald D. Breen. General Nutrition Centers, Inc. Reports Second Quarter 2008 Financial Results General Nutrition Centers, Inc. has announced FY08Q2 results, with reported revenues of $422.7 million, an 8.5% increase over the same quarter in 2007. This increase was the result of increased revenues in each of the Company's business segments: Retail by 6.3%; Franchise by 8.6%; and Manufacturing/Wholesale by 28.0%. Same store sales improved 4.5% in domestic company-owned stores (including internet sales), and 5.2% in Canadian stores General Nutrition Centers, Inc. Reports Second Quarter 2008 Financial Results General Nutrition Centers, Inc. has announced FY08Q2 results, with reported revenues of $422.7 million, an 8.5% increase over the same quarter in 2007. This increase was the result of increased revenues in each of the Company's business segments: Retail by 6.3%; Franchise by 8.6%; and Manufacturing/Wholesale by 28.0%. Same store sales improved 4.5% in domestic company-owned stores (including internet sales), and 5.2% in Canadian stores Sprunk-Jansen Launches Products Based On Greek-Arabic System, Opens US Office, Announces Staff Sprunk-Jansen have announced the opening of their U.S. operation, along with a new sales team, Chief Operating Officer, President of U.S. operations and others involved in the company. Newly available products are also introduced. Sprunk-Jansen Launches Products Based On Greek-Arabic System, Opens US Office, Announces Staff Sprunk-Jansen have announced the opening of their U.S. operation, along with a new sales team, Chief Operating Officer, President of U.S. operations and others involved in the company. Newly available products are also introduced. Sprunk-Jansen Launches Products Based On Greek-Arabic System, Opens US Office, Announces Staff Sprunk-Jansen have announced the opening of their U.S. operation, along with a new sales team, Chief Operating Officer, President of U.S. operations and others involved in the company. Newly available products are also introduced. Sprunk-Jansen Launches Products Based On Greek-Arabic System, Opens US Office, Announces Staff Sprunk-Jansen have announced the opening of their U.S. operation, along with a new sales team, Chief Operating Officer, President of U.S. operations and others involved in the company. Newly available products are also introduced. Sprunk-Jansen Launches Products Based On Greek-Arabic System, Opens US Office, Announces Staff Sprunk-Jansen have announced the opening of their U.S. operation, along with a new sales team, Chief Operating Officer, President of U.S. operations and others involved in the company. Newly available products are also introduced. Sprunk-Jansen Launches Products Based On Greek-Arabic System, Opens US Office, Announces Staff Sprunk-Jansen have announced the opening of their U.S. operation, along with a new sales team, Chief Operating Officer, President of U.S. operations and others involved in the company. Newly available products are also introduced. Senomyx Announces Second Quarter 2008 Financial Results Senomyx has announced FY08Q2 results, reporting Q2 revenues of $9.6 million for the six months ended June 30, 2008, compared to $6.8 million for the six months ended June 30, 2007. Senomyx Announces Second Quarter 2008 Financial Results Senomyx has announced FY08Q2 results, reporting Q2 revenues of $9.6 million for the six months ended June 30, 2008, compared to $6.8 million for the six months ended June 30, 2007. ChromaDex Completes $4.67 Million Capital Raise in Private Placement Transaction ChromaDex Corporation has announced that on July 29, 2008, it completed its last round of sales under a private placement. The private placement, which was authorized for up to $6 million and has been on-going since March, yielded gross proceeds of approximately $4.67 million. ChromaDex Completes $4.67 Million Capital Raise in Private Placement Transaction ChromaDex Corporation has announced that on July 29, 2008, it completed its last round of sales under a private placement. The private placement, which was authorized for up to $6 million and has been on-going since March, yielded gross proceeds of approximately $4.67 million. ChromaDex Completes $4.67 Million Capital Raise in Private Placement Transaction ChromaDex Corporation has announced that on July 29, 2008, it completed its last round of sales under a private placement. The private placement, which was authorized for up to $6 million and has been on-going since March, yielded gross proceeds of approximately $4.67 million. Omega Protein Reports Second Quarter Results Omega Protein Corporation has announced FY08Q2 results, reporting a Q2 income of $6.7 million ($0.37 per share) with a net income of $2.5 million ($0.15 per share) for the second quater of the previous year. Omega Protein Reports Second Quarter Results Omega Protein Corporation has announced FY08Q2 results, reporting a Q2 income of $6.7 million ($0.37 per share) with a net income of $2.5 million ($0.15 per share) for the second quater of the previous year. Omega Protein Reports Second Quarter Results Omega Protein Corporation has announced FY08Q2 results, reporting a Q2 income of $6.7 million ($0.37 per share) with a net income of $2.5 million ($0.15 per share) for the second quater of the previous year. NutraCea Announces Second Quarter 2008 Financial Results NutraCea (NTRZ) has announced FY08 Q2 results, reporting net revenues of $10.3 million for the second quarter of 2008, compared to net revenues of $13.0 million for the second quarter of 2007, with a one-time license fee of $5.0 million (non-recurring) without which net revenues for the second quarter 2007 would have been $8,000,000. Net loss for the second quarter of 2008 was $6.1 million, or $(0.04) per share, compared to net income of $2.0 million or $0.01 per share for the same period last year. NutraCea Announces Second Quarter 2008 Financial Results NutraCea (NTRZ) has announced FY08 Q2 results, reporting net revenues of $10.3 million for the second quarter of 2008, compared to net revenues of $13.0 million for the second quarter of 2007, with a one-time license fee of $5.0 million (non-recurring) without which net revenues for the second quarter 2007 would have been $8,000,000. Net loss for the second quarter of 2008 was $6.1 million, or $(0.04) per share, compared to net income of $2.0 million or $0.01 per share for the same period last year. KI NutriCare to Acquire Allergy Research Group for $1.33 Per Share in an All Cash Tender Offer Valued at Approximately $19,500,000 KI NutriCare, Inc. and Allergy Research Group, Inc. (ALRG) have announced that KI NutriCare, a wholly-owned subsidiary of Kikkoman Corporation (TSE:2801), Longhorn Acquisition Corp., a wholly-owned subsidiary of KI NutriCare formed to effect the transaction, and Allergy Research Group have entered into a definitive agreement pursuant to which Allergy Research Group will be acquired for approximately $19,500,000 through an all cash tender offer of $1.33 per share by Longhorn Acquisition Corp. KI NutriCare to Acquire Allergy Research Group for $1.33 Per Share in an All Cash Tender Offer Valued at Approximately $19,500,000 KI NutriCare, Inc. and Allergy Research Group, Inc. (ALRG) have announced that KI NutriCare, a wholly-owned subsidiary of Kikkoman Corporation (TSE:2801), Longhorn Acquisition Corp., a wholly-owned subsidiary of KI NutriCare formed to effect the transaction, and Allergy Research Group have entered into a definitive agreement pursuant to which Allergy Research Group will be acquired for approximately $19,500,000 through an all cash tender offer of $1.33 per share by Longhorn Acquisition Corp. Synutra Achieved 88.7% Net Sales Growth for the First Quarter Ended June 30, 2008 Company reports Q1 net sales in the first quarter ended June 30, 2008 increased by 88.7% to $127.4 million, compared to $67.5 million for the same quarter in 2007. First quarter net income increased by 193.0% to $15.6 million, compared to net income of $5.3 million in the same period in 2007. Synutra earned $0.29 per share (basic) in the first quarter of fiscal 2008, up 163.6% from $0.11 earned in the prior year period. Synutra Achieved 88.7% Net Sales Growth for the First Quarter Ended June 30, 2008 Company reports Q1 net sales in the first quarter ended June 30, 2008 increased by 88.7% to $127.4 million, compared to $67.5 million for the same quarter in 2007. First quarter net income increased by 193.0% to $15.6 million, compared to net income of $5.3 million in the same period in 2007. Synutra earned $0.29 per share (basic) in the first quarter of fiscal 2008, up 163.6% from $0.11 earned in the prior year period. Schiff Nutrition International, Inc. Announces Fiscal 2008 Fourth Quarter and Year-End Results Schiff Nutrition International, Inc., has announced FY08 Q4 results reporting net sales were $50.4 million for the three months ended May 31, 2008, compared to $43.2 million for the same period in fiscal 2007. For the fiscal 2008 fourth quarter, Schiff Nutrition reported net income of $2.8 million, or $0.10 per diluted share, compared to net income of $3.7 million, or $0.13 per diluted share, for the same period a year ago. Schiff Nutrition's net sales were $176.9 million for the year ended May 31, 2008, compared to $172.7 million for fiscal 2007. For fiscal 2008, Schiff Nutrition reported net income of $11.3 million, or $0.40 per diluted share, compared to net income of $12.4 million, or $0.45 per diluted share, for fiscal 2007. Schiff Nutrition International, Inc. Announces Fiscal 2008 Fourth Quarter and Year-End Results Schiff Nutrition International, Inc., has announced FY08 Q4 results reporting net sales were $50.4 million for the three months ended May 31, 2008, compared to $43.2 million for the same period in fiscal 2007. For the fiscal 2008 fourth quarter, Schiff Nutrition reported net income of $2.8 million, or $0.10 per diluted share, compared to net income of $3.7 million, or $0.13 per diluted share, for the same period a year ago. Schiff Nutrition's net sales were $176.9 million for the year ended May 31, 2008, compared to $172.7 million for fiscal 2007. For fiscal 2008, Schiff Nutrition reported net income of $11.3 million, or $0.40 per diluted share, compared to net income of $12.4 million, or $0.45 per diluted share, for fiscal 2007. Frutarom Second Quarter 2008 Results Release Scheduled for Tuesday, August 19, 2008 Frutarom announced that it will be releasing its second quarter 2008 results on Tuesday, August 19, 2008. The Company will also be hosting a conference call on the same day at 2:00pm UK time or 9:00am EDT. During the call, management will review and discuss the results and will be available to answer investor questions. Frutarom Second Quarter 2008 Results Release Scheduled for Tuesday, August 19, 2008 Frutarom announced that it will be releasing its second quarter 2008 results on Tuesday, August 19, 2008. The Company will also be hosting a conference call on the same day at 2:00pm UK time or 9:00am EDT. During the call, management will review and discuss the results and will be available to answer investor questions. Balchem Corporation's New Choline Memor-C Website Goes Live Balchem Corporation today announced its Food, Pharma and Nutrition segment has launched a new website to provide information on its food grade Choline product line, Memor-C(tm), for food fortification. Balchem Corporation's New Choline Memor-C Website Goes Live Balchem Corporation today announced its Food, Pharma and Nutrition segment has launched a new website to provide information on its food grade Choline product line, Memor-C(tm), for food fortification. Balchem Corporation's New Choline Memor-C Website Goes Live Balchem Corporation today announced its Food, Pharma and Nutrition segment has launched a new website to provide information on its food grade Choline product line, Memor-C(tm), for food fortification. ISI Brands Teams With The Vitamin Shoppe to Debut Dr. Alan Greene Nutritional Supplement Line ISI Brands, Inc./Twinlab(R) and renowned pediatrician Dr. Alan Greene have teamed with leading national health retailer The Vitamin Shoppe for the retail launch of Twinlab DrGreene(TM) line of nutritional supplements. The Vitamin Shoppe will debut the Dr. Greene nutritional supplement product line in mid-August, 2008 and will be celebrated with launch events in Vitamin Shoppe stores in San Francisco, New York, and Los Angeles. ISI Brands Teams With The Vitamin Shoppe to Debut Dr. Alan Greene Nutritional Supplement Line ISI Brands, Inc./Twinlab(R) and renowned pediatrician Dr. Alan Greene have teamed with leading national health retailer The Vitamin Shoppe for the retail launch of Twinlab DrGreene(TM) line of nutritional supplements. The Vitamin Shoppe will debut the Dr. Greene nutritional supplement product line in mid-August, 2008 and will be celebrated with launch events in Vitamin Shoppe stores in San Francisco, New York, and Los Angeles. ISI Brands Teams With The Vitamin Shoppe to Debut Dr. Alan Greene Nutritional Supplement Line ISI Brands, Inc./Twinlab(R) and renowned pediatrician Dr. Alan Greene have teamed with leading national health retailer The Vitamin Shoppe for the retail launch of Twinlab DrGreene(TM) line of nutritional supplements. The Vitamin Shoppe will debut the Dr. Greene nutritional supplement product line in mid-August, 2008 and will be celebrated with launch events in Vitamin Shoppe stores in San Francisco, New York, and Los Angeles. ISI Brands Teams With The Vitamin Shoppe to Debut Dr. Alan Greene Nutritional Supplement Line ISI Brands, Inc./Twinlab(R) and renowned pediatrician Dr. Alan Greene have teamed with leading national health retailer The Vitamin Shoppe for the retail launch of Twinlab DrGreene(TM) line of nutritional supplements. The Vitamin Shoppe will debut the Dr. Greene nutritional supplement product line in mid-August, 2008 and will be celebrated with launch events in Vitamin Shoppe stores in San Francisco, New York, and Los Angeles. ISI Brands Teams With The Vitamin Shoppe to Debut Dr. Alan Greene Nutritional Supplement Line ISI Brands, Inc./Twinlab(R) and renowned pediatrician Dr. Alan Greene have teamed with leading national health retailer The Vitamin Shoppe for the retail launch of Twinlab DrGreene(TM) line of nutritional supplements. The Vitamin Shoppe will debut the Dr. Greene nutritional supplement product line in mid-August, 2008 and will be celebrated with launch events in Vitamin Shoppe stores in San Francisco, New York, and Los Angeles. ChromaDex Announces Second Quarter 2008 Financial Results ChromaDex Corporation has announced their FY08 Q2 results, reporting a net loss attributable to common stockholders of $0.03 per share for the three months ended June 28, 2008. As of June 28, 2008, cash, cash equivalents, and marketable securities totaled approximately $2.4 million. Balance sheet cash, cash equivalents and marketable securities includes all but approximately $1.1 million in proceeds from the final closings of the $4.6 million private placement the Company and its subsidiary just concluded. ChromaDex Announces Second Quarter 2008 Financial Results ChromaDex Corporation has announced their FY08 Q2 results, reporting a net loss attributable to common stockholders of $0.03 per share for the three months ended June 28, 2008. As of June 28, 2008, cash, cash equivalents, and marketable securities totaled approximately $2.4 million. Balance sheet cash, cash equivalents and marketable securities includes all but approximately $1.1 million in proceeds from the final closings of the $4.6 million private placement the Company and its subsidiary just concluded. Forbes Medi-Tech Announces Second Quarter 2008 Financial Results Forbes Medi-Tech Inc. today announced its results for the second quarter 2008 ended June 30, 2008. Comparative period for these statements is the three- and six-month periods ended June 30, 2007. Forbes reiterates its financial outlook for the full year 2008 and continues to expect sales of $9.75 million to $10.5 million, an increase of up to 18% compared to its reported revenues in 2007. Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Spotlight on Savory Side Dishes Spotlight on Savory Side Dishes Spotlight on Savory Side Dishes Another Reason to Choose Healthy Lifestyle Habits Another Reason to Choose Healthy Lifestyle Habits	Capsugel, a global leader in dosage form development and manufacturing, has received certification from the Therapeutic Goods Administration (TGA), a division of the Australian Department of Health and Ageing, for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA). The TGA is Australia’s principal regulatory authority for all therapeutic goods, including pharmaceuticals, dietary and nutritional supplements, as well as complementary medicines. Lawful sale of such products in Australia requires that the product is included on the Australian Register of Therapeutic Goods (ARTG). To obtain certification, which is product-specific, a marketer must demonstrate compliance with TGA requirements. One such requirement is that the manufacturing operations used to produce the product meet the current Australian Code of Good Manufacturing Practice (GMP) for Medicinal Products. “The Australian GMP code is very thorough because it covers all medicines and is highly respected by many regulatory authorities around the world. In conjunction with the growing demand for products that utilize the Licaps liquid delivery system, our customers can now more readily access important global markets. Certainly, our experience is that the important benefits of the Licaps delivery system, which include heightened consumer preference and improved bioavailability, address global needs,” said Robert Whitelaw, Director of Sales, Marketing and Business Development for Capsugel’s Americas Region. With this TGA certification in place for a key manufacturing operation, marketers can more readily expand their product lines delivered via the Licaps technology into the Australian market – as well as elsewhere around the world because of the certification’s high credibility. “Capsugel is well positioned with the resources to help customers develop TGA certified products,” Whitelaw concluded. ******************************************* Capsugel, a world leader in dosage form development and manufacturing, produces two-piece gelatin and vegetarian capsules for nutraceutical, pharmaceutical and over-the-counter (OTC) markets. The Capsugel product line of uniquely designed and patented products includes Licaps® liquid capsules, Vcaps® and Vcaps® Plus vegetarian capsules, and DBcaps® capsules for double-blind clinical trials. The company also customizes liquid-fill formulas with laboratories in both the US and Europe. Capsugel is a division of Pfizer Inc. For more information visit www.capsugel.com or call (888) 783-6361.
Powered By Traffic Booster Absolute News Manager Plug-in by Xigla Software